Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Giovanna Garufi
Observed names:
G Garufi,
G. Garufi,
Garufi, Giovanna,
Giovanna GARUFI
Institutions:
Università Cattolica del Sacro Cuore,
Agostino Gemelli University Polyclinic,
Istituti di Ricovero e Cura a Carattere Scientifico
Observed institutions:
Università Cattolica del Sacro Cuore,
Agostino Gemelli University Polyclinic,
Karolinska Institutet,
Istituti di Ricovero e Cura a Carattere Scientifico
ORCID:
0009-0001-1800-2122
Observed ORCID:
0009-0001-1800-2122
OpenAlex ID:
A5064229545
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
2021
·
Khalid El Bairi
, Harry R. Haynes
, et al.
·
npj Breast Cancer
·
314
PDF
Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome
2023
·
Linda Cucciniello
, Giovanna Garufi
, et al.
·
Cancer Treatment Reviews
·
80
PDF
Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors
2020
·
Giovanna Garufi
, Antonella Palazzo
, et al.
·
Expert Opinion on Pharmacotherapy
·
63
Smoking habit and hospitalization for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related pneumonia: The unsolved paradox behind the evidence.
2020
·
Giovanna Garufi
, Luisa Carbognin
, et al.
·
European Journal of Internal Medicine
·
43
PDF
Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents
2022
·
Giovanna Garufi
, Luisa Carbognin
, et al.
·
Cancers
·
29
PDF
Treatment of Locally Advanced Gastric Cancer (LAGC): Back to Lauren’s Classification in Pan–Cancer Analysis Era?
2020
·
Ina Valeria Zurlo
, Michele Basso
, et al.
·
Cancers
·
25
PDF
Case report: Vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: two cases of premature interruption of therapy and exceptional response
2023
·
Mariangela Pasqualoni
, Armando Orlandi
, et al.
·
Frontiers in Oncology
·
22
PDF
Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?
2022
·
Giovanna Garufi
, Luisa Carbognin
, et al.
·
Cancer Treatment Reviews
·
21
The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis
2023
·
Luca Mastrantoni
, Armando Orlandi
, et al.
·
EClinicalMedicine
·
16
The Therapeutic Challenge of Disseminated Bone Marrow Metastasis From HR-Positive HER2-Negative Breast Cancer: Case Report and Review of the Literature
2021
·
Giovanna Garufi
, Luisa Carbognin
, et al.
·
Frontiers in Oncology
·
15
PDF
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy
2025
·
Luca Mastrantoni
, Giovanna Garufi
, et al.
·
npj Breast Cancer
·
12
PDF
Adjuvant denosumab in early breast cancer: a systematic review and meta-analysis of randomized controlled clinical trials
2023
·
Luca Mastrantoni
, Giovanna Garufi
, et al.
·
Therapeutic Advances in Medical Oncology
·
12
PDF
Liver Metastasectomy for Metastatic Breast Cancer Patients: A Single Institution Retrospective Analysis
2021
·
Armando Orlandi
, Letizia Pontolillo
, et al.
·
Journal of Personalized Medicine
·
11
PDF
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation
2022
·
Maria Vittoria Dieci
, Luisa Carbognin
, et al.
·
British Journal of Cancer
·
10
PDF
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy
2023
·
Giovanna Garufi
, Luisa Carbognin
, et al.
·
Therapeutic Advances in Medical Oncology
·
9
FOLFOX rechallenge versus regorafenib in patients with metastatic colorectal cancer refractory to standard chemotherapy: A retrospective analysis.
2019
·
Maria Alessandra Calegari
, Ina Valeria Zurlo
, et al.
·
Journal of Clinical Oncology
·
7
Activity and Efficacy of Neoadjuvant Chemotherapy in Luminal-HER2 Negative Early Breast Cancer According to HER2 Score (Low vs. Score 0): A Retrospective Study
2025
·
Giovanna Garufi
, Luca Mastrantoni
, et al.
·
Clinical Breast Cancer
·
6
PDF
Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2− Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series
2020
·
Armando Orlandi
, Elena Iattoni
, et al.
·
Journal of Personalized Medicine
·
6
PDF
Monoinstitutional real world experience in management of Vinflunine as second line therapy for transitional cell carcinoma of the urothelium
2018
·
Giovanni Schinzari
, Ernesto Rossi
, et al.
·
Oncotarget
·
6
PDF
Artificial intelligence (AI) –based machine learning models (ML) for predicting pathological complete response (pCR) in patients with hormone receptor (HoR) –positive/HER2-negative early breast cancer (EBC) undergoing neoadjuvant chemotherapy (NCT): A retrospective cohort study.
2023
·
Luca Mastrantoni
, Giovanna Garufi
, et al.
·
Journal of Clinical Oncology
·
5
PDF
Predicting progression-free survival in hormone-receptor positive (HR+/HER2–) metastatic breast cancer (MBC) treated with CDK4/6 inhibitors: A machine learning approach
2026
·
Sergio Pannunzio
, Luca Mastrantoni
, et al.
·
The Breast
·
4
PDF
Bone Health and Endocrine Therapy with Ovarian Function Suppression in Premenopausal Early Breast Cancer: A Real-Life Monocenter Experience with Denosumab
2025
·
Angelachiara Rotondi
, Valentina Frescura
, et al.
·
Current Oncology
·
4
PDF
Tolerability and Preliminary Outcomes of Adjuvant T-DM1 in HER2-Positive Breast Cancer After Neoadjuvant Therapy: The ATD Study
2024
·
Eriseld Krasniqi
, Lorena Filomeno
, et al.
·
Cancers
·
4
PDF
Outcomes of Radiotherapy in Oligoprogressive Breast Cancer
2024
·
Fabio Marazzi
, Valeria Masiello
, et al.
·
Journal of Personalized Medicine
·
4
Comparison of machine learning and deep learning models for survival prediction in early-stage hormone receptor-positive/HER2-negative breast cancer receiving neoadjuvant chemotherapy
2025
·
L. Mastrantoni
, G. Garufi
, et al.
·
ESMO Real World Data and Digital Oncology
·
3
PDF
Show more works
View as search
Works count:
55
Citation count:
747
H-index:
12
I10-index:
14
Year
Topic
Type